Skip to main content

Table 3 Treatment predicting infections, for all persons and among those deficient in 25(OH)D at baseline at varying thresholds

From: Weekly cholecalciferol supplementation results in significant reductions in infection risk among the vitamin D deficient: results from the CIPRIS pilot RCT

  Number of participants with baseline 25(OH)D at level specified (%) All infections Infections seen in clinic
Unadjusted Adjusteda Unadjusted Adjusteda
All persons Placebo 16 (47.1) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
0.83 (0.53, 1.31) 0.80 (0.50, 1.30) 0.86 (0.50, 1.50) 0.87 (0.52, 1.46)
Treatment 18 (52.9) P = 0.42 P = 0.37 P = 0.60 P = 0.60
25(OH)D threshold (nmol/L) ≤40 Placebo 2 (50.0) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 2 (50.0) 0.56 (0.32, 0.96)b 0.41 (0.22, 0.78)b 0.27 (0.07, 1.00)b 0.26 (0.06, 1.17)
P = 0.036b P = 0.007b P = 0.050b P = 0.079
≤50 Placebo 4 (50.0) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 4 (50.0) 0.61 (0.38, 0.98)b 0.68 (0.34, 1.34) 0.48 (0.18, 1.30) 0.57 (0.18, 1.78)
P = 0.043b P = 0.27 P = 0.15 P = 0.34
≤60 Placebo 4 (40.0) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 6 (60.0) 0.86 (0.54, 1.35) 1.02 (0.60, 1.72) 0.66 (0.34, 1.30) 0.74 (0.36, 1.56)
P = 0.50 P = 0.95 P = 0.23 P = 0.43
≤70 Placebo 5 (29.4) 1.00 [reference] 1.00 [reference] 1.00 [reference] 1.00 [reference]
Treatment 12 (70.6) 0.80 (0.51, 1.25) 0.82 (0.48, 1.41) 0.95 (0.46, 1.97) 0.85 (0.42, 1.70)
P = 0.33 P = 0.48 P = 0.89 P = 0.64
  1. Results are presented as HR (95% CI).
  2. 25(OH)D 25-hydroxyvitamin D, nmol/L nanomoles per litre.
  3. aAnalyses adjusted for age, sex, ever smoking and days per week engaging in vigorous physical activity.
  4. bStatistically significant.